Unlocking potential: The impact of CRISPR in organoid research

This exclusive article is by Dr. Ralph Vogelsang, Senior Director of Business Development & Licensing, ERS Genomics. Conventional drug discovery models, such as animal models or human cell lines, often fail due to their divergence...

New antibiotic ‘evades bacterial resistance’

A promising new weapon has emerged in the fight against drug-resistant bacteria and resultant diseases, writes Rob Mitchum. The antibiotic cresomycin - described in Science - effectively suppresses pathogenic bacteria that have become resistant to...

Europe’s ‘disappearing’ generic medicines are a growing crisis

Europe’s critical medicine cabinets – in hospitals, pharmacies, and homes – are home to fewer generic medicines. These are the often-cheaper alternatives to brand name medicines, that make up 67%1 of all medicines. Research from Teva...

Tiny sea microbes could unlock new cures

Off the coast of Spain, studies of the marine microbiome are opening new doors for pharmacology, writes Claudia Alemañy Castilla. The island of Tabarca, near Alicante, is a tourist magnet. It’s also a working platform...

Breaking new ground in antibiotic research with neutrons

Dr Luke Clifton, Instrument Scientist at ISIS Neutron and Muon Source, explains how neutrons have emerged as a highly effective tool in the fight against AMR. Antimicrobial resistance (AMR) has been one of the biggest...

£25m funding for future vaccine development

Three ambitious research projects designed to build our understanding of viruses and how the immune system reacts to different challenges will share £25 million in new funding from UK Research and Innovation (UKRI). Tackling Infections...

Pain killers made from pine trees instead of crude oil

Common drugs such as paracetamol and ibuprofen can be made from a chemical from pine trees instead of crude oil products. A team of scientists, from the University of Bath’s Department of Chemistry and Institute...

‘World-first’ immunotherapy drug designed by generative AI

British techbio innovator Etcembly has kickstarted the next generation of immunotherapies with a pipeline of best-in-class T cell receptor (TCR) therapeutics designed using generative AI. The company’s lead therapeutic programme, ETC-101, is the world’s first...

Emerging biotechs jumpstart drug commercialisation via out-licencing – a Deloitte analysis

By Hanno Ronte, life sciences and healthcare partner at Deloitte. Examining the various go-to-market strategies deployed by emerging biotech companies when launching their first product into Europe reveals how the frequencies of these strategies changed...

Cellular ‘traffic controllers’ caught managing flow of signals from receptors

 First time that individual beta-arrestin molecules are directly observed as they control receptor-mediated signals in living cells using advanced microscopy.   New findings could inform the development of better drugs for pain relief,...

Life-saving cancer drug takes a major step closer to patient care

A new drug candidate for hard-to-treat cancers, discovered at the University of Edinburgh and licensed by biopharmaceutical company Nuvectis Pharma, Inc. (“Nuvectis” or “Company”), can now begin clinical trials as announced by Nuvectis. The compound,...

Biochemical synthesis breakthrough could unlock new medicines

A mystery about lab synthesis of a natural chemical compound may have been solved – a breakthrough which could unlock new developments in medicine. Scientists in Scotland and Germany made the discovery, published in the...

Hijacking our cell enzymes to eliminate disease-causing proteins

By studying how enzymes move from one membrane compartment to another inside a cell, scientists at the University of Illinois Chicago have figured out a way to better target cellular proteins, which play a...

New drugs partnership tackles lung disease

Aston University scientists are working with start-up company, Isterian Biotech, part of Cambrian BioPharma, to develop novel drugs to treat fibrotic diseases such as lung disease. The focus of preclinical-stage biotechnology company Isterian Biotech is...